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The prices people pay for medicines in Zimbabwe
*P GAVAZA, * *T SIMOYI, ***B MAKUNIKE, ****CC MAPONGA
Abstract
O bjectives: To collect, analyse and com pare prices o f  m edicines in different sectors and parts o f  the country 
and to com pare them  w ith the m edicine prices in o ther countries.
D esign : A  prospective cross sectional study.
S e ttin g :  Pharm acy outlets in Z im babw e com prising 27 retail pharm acies, 23 dispensing doctors, eight public 
hospital pharm acies and seven m unicipal clinics.
M a in  O utcom e M easures:  M edian price ratios, 25th percentiles and 75,h percentiles.
R esu lts:  Innovator brands in the private sector w ere p riced  10 tim es the International R eferences Prices (IRP) 
and m ore than three tim es the price o f  generic m edicines. D ispensing doctors w ere charging the h ighest prices 
for m edicines and the public  sector had the least prices. The national procurem ent agency, N atPharm , 
procured  m edicines at prices slightly  below  the M anagem ent Sciences for H ealth  (M SH ) prices. Prices o f  
m edicines in the public  sector w ere h igher than  average prices for m edicines from  seven other A frican 
countries.
C onclusion:  M edicine prices in  Z im babw e are high, a scenario that m ay com prom ise affordability  and 
accessibility  to m edicines especially  by  the poor. U rgent steps are needed to  reduce the level and effect o f  the 
h igh prices on the population, especially  the poor.
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Introduction
People need drugs to maintain health and for relief 
from pain, suffering and ill health. But drugs have to be 
bought. They have to be bought in foreign currency, 
including a part of those produced locally. They are 
expensive and the price is going up every day.1 In many 
developing countries, medicines are unaffordable to 
the majority o f people. The cost of health care and 
particularly the cost o f prescription medicines presents 
major challenges to public expenditure policies.2
Medicine costs account for a large proportion o f  
households', insurers and governm ents' health 
spending in many African countries, including 
Zimbabwe. It has been estimated that up to 50% of the 
population in Africa and Asia are unable to obtain 
necessary medicines.3 The price o f medicines is one of 
the most important obstacles to access. The cost of 
pharmaceuticals in the overall budgets o f insurers and 
governments continues to be targeted and often 
become controversial issues.4 Poverty, declining 
national economy, foreign currency shortages, low 
insurance coverage and the high HIV/AIDS disease
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burden have further compounded the problem o f access 
to affordable medicines by the population, especially 
the poor. The above factors have made it difficult for 
the Zimbabwe National Drug Policy to realize its goal 
o f having 90% or more o f essential drugs available in 
all public health facilities in the country. Public sector 
surveys conducted in Zimbabwe over the years show 
that none o f  the levels o f health facilities in the country 
achieved the 90% overall drug availability target.5 
The formulation of well informed and appropriate 
pricing policies requires the availability of reliable 
information on medicine prices. While Zimbabwe and 
many other developing countries have policies that 
affect medicine prices, lack of accurate information on 
the actual price o f medicines paid by patients makes it 
difficult to assess how well the pricing policies are 
working. This study was conducted to analyse and 
compare the prices of medicines in the different parts of 
the health sector in the country and to compare them 
with those in other African countries.
Experimental.
A prospective study was conducted using the WHO and 
Health Action International (HAI) methodology as 
stipulated in the manual “Medicine prices: a new 
approach to measurement”.6 The study was conducted 
as part of the broader Zimbabwe Medicines Survey 
20047 and was conducted concurrently with similar
Table I: Core and supplementary medicines used.
studies in seven other African countries during the last 
quarter o f2004.
The standardised WHO/HAI questionnaire (data 
collection form) was used to collect medicines prices 
information from a sample o f health institutions in 
the country. The first section included four questions 
covering the name of health facility, name of town or 
district, type of health facility, type of price (i.e., 
procurement or price the patient pays). The second 
section was the medicine price data collection form 
which was designed to collect data on the prices 
patients paid for medicines. The form had a listing of 
42 medicines including 29 on the WHO/HAI 
standard list. The use of this standard list of 
medicines allowed for international comparison of 
the study results. In addition to medicines in the core 
list, a supplementary list o f  13 medicines was added. 
In developing the supplementary list consideration 
was given to the burden o f disease, local production 
and availability of fixed dose combination products. 
The substances added were those widely used in the 
country and were taken from the Essential Drugs List 
of Zimbabwe (EDLIZ).8 To facilitate national and 
international comparison of results, only medicines 
with Management Sciences for Health (MSH) 
reference prices were included in the final list (Table
I) o f medicines surveyed.
No.
Medicine Name Medicine
Strength
Dosage
Form
Target 
Pack size
Core List 
(Yes/No)
1 Aciclovir 200  mg cap/tab 25 yes
2 Amitriptyline 25  mg cap/tab 100 yes
3 Amoxicillin caps/tab 250  mg cap/tab 21 yes
4 Amoxicillin suspension 125 mg millilitre 100 no
5 Artesunate 100 mg cap/tab 20 yes
6 Atenolol 50  mg cap/tab 60 yes
7 B edom etaso ne inhaler 0 .0 5  mg/dose dose 200 yes
8 Betam ethasone 1%  cream 0.01 gram 50 no
9 Captopril 25  mg cap/tab 60 yes
10 Carbam azepine 2 0 0  mg cap/tab 150 yes
11 Ceftriaxone injection 1 g/vial gram 1 yes
12 Chloroquine 150 mg base tab 1000 no
13 Cim etidine 4 0 0  mg tab 100 no
14 Ciprofloxacin 500  mg cap/tab 1 yes
15 Co-trim oxazole suspension 8 + 4 0  mg/ml millilitre 70 yes
16 Cotrim oxazole tab 8 0 + 4 0 0  mg tab 1000 no
17 D iazepam 5 m g cap/tab 100 yes
18 Diclofenac 2 5  m g cap /tab 100 yes
19 Doxycydine 100  mg cap/tab 500 no
20 Erythromycin 2 5 0  mg cap /tab 1000 no
21 Fluconazole 2 0 0  mg cap/tab 30 yes
22 Fluoxetine 2 0  mg cap/tab 30 yes
23 Fluphenazine injection 2 5  mg/ml millilitre 1 yes
24 Glibenclam ide 5  mg cap /tab 6 0 yes
25 Hydrochlorothiazide 2 5  mg cap/tab 30 yes
26 Ibuprofen 2 0 0  mg cap/tab 500 no
27 Indinavir 4 0 0  mg cap /tab 180 yes
28 Indomethacin 2 5  mg cap /tab 1000 no
29 Losartan 50  mg cap /tab 30 yes
30 Metformin 5 0 0  mg cap/tab 100 yes
31 M etronidazole 2 0 0  mg tab 1000 no
32 Miconazole oral gel 2 %  cream gram 40 no
33 Nevirapine 2 0 0  mg cap/tab 60 yes
34 Nifedipine Retard 2 0  mg tab 100 yes
35 O m eprazole 20  mg cap /tab 30 yes
36 Phenytoin 100 mg cap/tab 100 yes
37 Prednisolone 5  mg tab 1000 no
38 Ranitidine 1 50  m g cap /tab 6 0 yes
39 Salbutam ol inhaler 0.1 m g/dose dose 2 00 yes
40 Stavudine+Lam uvudine+Nevirapine 4 0 + 1 5 0 + 2 0 0 cap/tab 60 no
41 Sulfadoxine-pyrim etham ine 5 0 0 + 2 5  mg cap/tab 3 yes
42 Zidovudine 100 mg cap/tab 150 yes
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For each medicine, three products were monitored, 
where available, including:
1) The innovator brand: the product made by the 
innovator;
2) Most sold generic equivalent: comprised the 
generic product that is most sold in the country. This 
was obtained prior to the data collection through an 
initial (national) survey o f the major wholesalers, 
private retail pharmacies and public sector institutions 
in Zimbabwe; and
3) Lowest price generic equivalent: the generic 
equivalent medicine with the least price. This was 
identified at each institution visited. The lowest price 
generic equivalent identified in each pharmacy did not 
need to be the same for all institutions but could vary 
from one institution to the other.
For each medicine, data collectors ascertained if  the 
medicine was available, and then recorded the pack 
size found and its price. This information was later used 
to calculate the unit price for each o f the medicines 
found.
A pilot study was undertaken during a weeklong field 
practice. Data collection was completed in four weeks 
(September to October 2004). Price data was collected 
from public sector (provincial and central hospitals and 
municipal clinics) and private sector (private retail 
pharmacies and dispensing doctors) institutions. The 
study was conducted in five randomly selected 
provinces o f the 10 provinces in the country, namely 
H arare  (in c lu d in g  C h itu n g w iza), M asv ingo , 
Bulawayo, M anicaland and M ashonaland West 
provinces. The study used the sampling method 
described in the WHO/HAI manual for selecting a 
representative number o f health facilities and 
pharmacies. All the central and provincial hospitals in 
the selected geographic areas were surveyed. Retail 
pharmacies and dispensing doctors were randomly 
selected using the most recent Medicines Control 
Authority o f Zimbabwe (MCAZ)9 lists. Municipal 
clinics were conveniently selected during data 
collection as no accurate lists were available before 
going to the field. A total o f 25 private retail 
pharmacies, eight public (central and provincial 
hospitals) sector health facilities, 25 dispensing doctors 
and seven municipal clinics were planned to participate 
in the study.
The study also collected secondary information on the 
national pharmaceutical situation in the country and 
procurement prices (tender prices) from the national 
government procurement agency, NatPharm.
Data were entered and analysed using a computerised 
WHO/HAI International Medicine Price Workbook, 
which is a special application for Microsoft Excel. 
Summary measures o f the medicine prices found 
during the survey were expressed as ratios relative to 
the MSH 2003 price list which was selected as a 
standard set o f reference prices. The use o f an 
international reference price allowed for standardised 
international comparison. Comparisons were done in 
local currency.
The study also compared the national prices in 
Zimbabwe with prices in other countries. Prices in local 
currency were converted to US dollars for comparison. 
Findings on medicines prices in this study are 
expressed mostly as “median price ratios” or MPRs. 
The MPR is a ratio o f the local price, in US dollars, over 
an international reference price (also in US dollars). 
The reference price was used as an external standard 
for evaluating local prices. To obtain an MPR for a local 
medicine, the Excel Workbook calculated the median 
among all the prices gathered during the field survey 
for that medicine in a sector. This is the “typical” local 
price charged to patients in that sector. The Workbook 
converted this typical local price into US dollars, and 
then divided that amount by the reference price for the 
same medicine. The resulting MPR shows how many 
times higher or lower the local price is, compared to the 
external international standard price. Median price 
ratios for a particular drug or sector were calculated and 
reported only in cases where the drug was found in at 
least four institutions.
Results
All the targeted pharmacy institutions (i.e., 27 private 
retail pharmacies, 23 dispensing doctors eight public 
hospitals and seven municipal clinics) were surveyed 
in the study. The prices o f innovator brand products 
in the retail pharmacy sector were found to be 10 
times the MSH international reference prices (IRP) 
(Table II). Dispensing doctors had the highest generic 
medicine prices which were over eight times the IRP 
and approximately twice the patient prices in the 
other three sectors surveyed. Generic medicine prices 
in the private retail sector were one third o f the prices 
for the innovator brands (Table II).
Table II: Medicine prices across sectors.
Sector Median Price Ratios
Innovator
Brand
Most Sold 
Generic
Lowest
Price
Generic
Retail pharmacy 
sector
9.82 3.64 3.35
Public hospitals - 2.59 2.57
Dispensing doctors - 7.86 7.86
Municipal clinics - 4.52 4.05
Public procurement 
prices
0.91 0.99
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P y rim e th a m in e  + s u lf a d o x in e ,  d ia z e p a m , 
indomethacin and chloroquine had very high prices. In 
the dispensing doctors sector, they were selling for at 
least 20 times the IRP. Prices o f a few medicines were 
below the IRP in both the private and dispensing 
doctors sectors (e.g., Lorsatan and Betamethasone 1%
cream).
Public sector hospitals sold medicines at prices 226% 
and 169% higher than the Natpharm procurement 
prices for the least priced generic (LPG) medicines 
respectively (Table III).
Table III: Price ratios and summary ratios in the public sector.
Procurement Public Sector No. Of Ratio
Sector MPR (n=2) MPR (n=8) medicines in private to
both sectors public
Most sold generic (MSG) 
equivalent
Lowest price generic 
(LPG)
The prices charged for the MSG and LPG medicines in private sector in general though Glibenclamide and
the private sector were 54% and 22% higher Hydrochlorothiazide were cheaper in the private sector
respectively than the prices in the public sector (Table than in the public sector.
IV). The public sector has lower patient prices than the
Table IV: Medicines prices in the public and private sectors.
Public Sector 
MPR (n=8)
Private Sector 
MPR (n=27)
No. of
medicines in 
both sectors
Ratio 
private to 
public
Most sold generic equivalent 2.57 3.72 12 154.0%
Lowest price generic 2.89 3.44 25 122.3%
equivalent
The prices charged for the least priced generic higher than the public sector medicine prices (Table V).
medicines in the dispensing doctors sector were 155%
Table V: Comparison o f  medicine prices between dispensing doctors and public sectors.
Public Sector Disp. Doctors No. of Ratio Disp.
MPR (n-8) Sector MPR medicines in Doctors to
(n=23) both sectors public
Most sold generic equivalent 3.06 13.28 10 433.2%
Lowest price generic 3.17 8.09 24 255.1%
equivalent
0.94 3.06 10 325.5%
0.97 2.61 19 268.6%
The Zim babw ean public procurem ent agency, 
NatPharm, on average procures medicines for 13 US 
cents more than the average prices from eight African
countries (including Zimbabwe). The public sector 
patient prices in Zimbabwe are, on average, 78 US 
cents more than the median prices in eight African
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countries. The prices o f medicines in Zimbabwe are 
higher than prices charged in other African countries 
(Table VI). However, the prices of medicines sold in the 
private sector were on average slightly less than the 
average, prices in the other African countries that 
participated in the study.
Table VI: Comparisons o f  medicine prices with prices 
in other African countries.
Sector Zimbabwe
MPRs
Average prices in 8 
African countries 
(25“'-75"' Percentile)
Public procurement 
LPG
0.99 0.86 (0.65-1.16)
Public sector 
patient LPG
2.89 2.11 (1.25-2.78)
Private pharmacy 
patient LPG
3.44 3.56 (3.04-4.41)
Discussion
The study results confirm that prices o f medicines in 
Zimbabwe are high. Medicine prices were highest in 
the dispensing doctors sector. The finding that some 
generic products were being sold for over 20 times the 
IRP is disturbing and raises questions about the way 
medicines are priced in the country. This may be 
indicative of the arbitrary nature of the setting of prices 
of medicines in the country.
There are large medicine price differences between 
the public, private retail pharmacies and dispensing 
doctors sectors with the public sector having relatively 
lower prices. The public sector hospitals charge lower 
prices to patients for the majority o f the medicines 
studied. In the private sector, even the cheapest generic 
medicines cost 22.3% more than the prices paid by 
patients in the public sector. Given the limited 
availability o f  medicines in the public sector 
institutions, many patients are forced to buy their 
medicines from the private sector institutions which are 
pricier. This is a common finding in poor countries with 
poorly regulated pharmaceutical sectors.
The prices o f innovator brands in the private sector 
was very high vis-a-vis the prices o f generic equivalent 
medicines (a very high brand premium). The prices of 
innovator brand products were, on average, three times 
the price o f generic medicines in the private sector. This 
finding supports the need for accelerated generic 
competition.
Public procurement by NatPharm through the 
international competitive tender system allows the 
country to purchase medicines at relatively low prices 
on the international market compared to prices for the 
private sector. The support exchange rate offered to 
NatPharm by the government for procurement o f drugs 
has also contributed to the low procurement prices vis­
a-vis the other sectors in the country. More competitive 
prices can be obtained through bulk purchases (pooled 
procurement). This can be achieved if  Natpharm could 
be more involved in the supply and distribution of 
essential medicines for the private sector as well as the 
public sector, than is currently taking place at the 
moment. However, comparison o f Zimbabwe public 
procurement prices with other African countries 
revealed that the country, on average, pays more for 
drugs than other African countries. This situation 
cannot be allowed to continue.
There were minor price differences between generic 
medicines (i.e. MSG and LPG medicines) in all the 
sectors surveyed. The minor differences between these 
types of medicines may indicate the existence of 
generic competition which is a positive development. 
The availability of more generic products on the market 
will help curb price increases.
Routine price monitoring (i.e. quarterly price surveys) 
should be conducted in Zimbabwe, given that better 
information on price, prices differences and factors 
contributing to the final cost o f a medicine are essential 
if the country is to find ways of making medicines more 
affordable.6
Our study had several potential limitations. First, the 
survey gives only a snapshot of the medicine price 
situation in the country and does not provide 
information on the trends o f these prices overtime. 
Second, the study used the official exchange rate o f the 
Zimbabwean dollar to the US dollar. At the time o f the 
study, the official exchange rate o f $5 616.16 to one US 
dollar was just 10% lower than the parallel market 
exchange rate which gives a more market related value 
o f the currency given the distortions in the valuing of 
the local currency. This may have had an effect of 
increasing the US dollar prices o f medicines in 
Zimbabwe. Given that it was applied across the board, 
this did not have an effect on internal comparisons.
Third, the use o f MSH IRP in comparing retail prices 
was not comparing like with like. The MSH reference 
prices are the medians o f recent procurement or tender 
prices offered by not-for-profit suppliers to developing 
countries for multi-source products. The use of IRP did 
not affect inter-country price comparisons and 
international comparisons as all the other countries 
used the same reference prices.
Fourth, the study examined 42 mostly used medicines 
in the country. Analysing these medicines may have 
introduced bias because the most commonly used 
medicines may represent those with lower prices. 
However, the medications used in the study are similar 
to the most prescribed medications in Zimbabwe.
Conclusion
The prices paid by people for medicines in Zimbabwe 
are high. Concerted measures and steps are urgently
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needed in order to improve access to and affordability 
of essential medicines for all.
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